Top BioTech SMidcap Stock: Mizuho Analyst Highlights IMMX
Mizuho analyst Graig Suvannavejh named Immix Biopharma (IMMX) as his top September pick, raising the price target to $26 from $15. The upgrade is based on the potential of NXC-201, a drug for relapsed/refractory AL amyloidosis, with projected peak global revenue of $1 billion. Immix shares have gained 133% year-to-date, outperforming the broader biotech sector. The company reported a net loss of $0.18 per share for Q2 2026.
How this was made
The 30-second read
Why it matters
The analyst upgrade and higher target could trigger buying pressure ahead of the NEXICART‑2 data release, offering a short‑term trade idea.
Market read
Provides a fresh catalyst for IMMX and may influence sentiment across the biotech sector.
What to watch
Potential competition and the need for FDA approval could delay commercialization.
Background
Mizuho analyst Graig Suvannavejh highlighted Immix Biopharma (IMMX) as a top small‑midcap biotech pick, raising the price target and noting an upcoming Phase 2 readout.
Ticker impact
Mizuho raised its price target to $26 and upgraded to Outperform, citing upcoming Phase 2 data for NXC-201 and a new indication.
Potential short-term rally as investors price in the upgraded target and upcoming trial results.
The upgrade is based on a revised revenue model and a near-term catalyst; such analyst actions historically move small-cap biotech stocks.
Market effects
Highlights renewed investor interest in AL amyloidosis therapies, may lift peer biotech valuations.
Primarily U.S. small‑cap biotech market.
Limited to biotech investors; no broad macro effect.
Counterpoint
The $1‑$3 B revenue projections may be overly optimistic given early‑stage data.
Key entities
- companyImmix Biopharma, Inc.
Biotech firm developing NXC-201 for AL amyloidosis.
- financial_institutionMizuho Securities
Research firm issuing the upgrade and price target.